ArticleNpj imaging2026
Low molecular weight 4,4'-quinocyanines for in vivo NIR-II fluorescence imaging.
Article in Npj imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SLC Transporter-Mediated Functional Imaging in Cancer Diagnosis.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Fluorescence-guided surgery (FGS) is limited by the shallow penetration and high autofluorescence of currently available NIR-I fluorophores. To address these constraints, we developed a class of low molecular weight organic fluorophores, 4,4'-quinocyanines (QuCy), that extend emission into the NIR-II (950-1700 nm) region. Rational design through substitution of indolenine head groups with N-substituted quinolinium moieties enhanced π-conjugation, reduced HOMO-LUMO gaps, and induced bathochromic shifts of up to 225 nm, confirmed by density functional theory and spectroscopic analyses. Five derivatives (JAM317-319, JAP331, JAP334) were synthesized via a modular route and exhibited emission maxima of 976-1004 nm. Compared with NIR-I dyes, QuCy dyes demonstrated improved depth penetration and contrast due to reduced tissue autofluorescence. In vivo evaluation of JAM317 revealed efficient tumor cell uptake, low cytotoxicity, and high-resolution vascular imaging. These findings establish QuCy dyes as a promising platform for clinically translatable NIR-II contrast agents.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.